Logo image of MYNZ

MAINZ BIOMED NV (MYNZ) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MYNZ - NL0015000LC2 - Common Stock

1.03 USD
-0.02 (-1.9%)
Last: 12/12/2025, 8:00:01 PM
1.07 USD
+0.04 (+3.88%)
After Hours: 12/12/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, MYNZ scores 2 out of 10 in our fundamental rating. MYNZ was compared to 529 industry peers in the Biotechnology industry. Both the profitability and financial health of MYNZ have multiple concerns. MYNZ is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MYNZ had negative earnings in the past year.
In the past year MYNZ has reported a negative cash flow from operations.
In the past 5 years MYNZ always reported negative net income.
In the past 5 years MYNZ always reported negative operating cash flow.
MYNZ Yearly Net Income VS EBIT VS OCF VS FCFMYNZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

MYNZ has a Return On Assets of -220.85%. This is amonst the worse of the industry: MYNZ underperforms 91.15% of its industry peers.
With a Return On Equity value of -858.34%, MYNZ is not doing good in the industry: 79.85% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -220.85%
ROE -858.34%
ROIC N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYNZ Yearly ROA, ROE, ROICMYNZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

MYNZ has a Gross Margin of 64.31%. This is in the better half of the industry: MYNZ outperforms 79.85% of its industry peers.
MYNZ's Gross Margin has improved in the last couple of years.
MYNZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
MYNZ Yearly Profit, Operating, Gross MarginsMYNZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

1

2. Health

2.1 Basic Checks

MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYNZ has been increased compared to 1 year ago.
The number of shares outstanding for MYNZ has been increased compared to 5 years ago.
The debt/assets ratio for MYNZ has been reduced compared to a year ago.
MYNZ Yearly Shares OutstandingMYNZ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
MYNZ Yearly Total Debt VS Total AssetsMYNZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -16.31, we must say that MYNZ is in the distress zone and has some risk of bankruptcy.
MYNZ's Altman-Z score of -16.31 is on the low side compared to the rest of the industry. MYNZ is outperformed by 81.92% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that MYNZ is not too dependend on debt financing.
MYNZ has a worse Debt to Equity ratio (0.44) than 71.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -16.31
ROIC/WACCN/A
WACC6.09%
MYNZ Yearly LT Debt VS Equity VS FCFMYNZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 0.52 indicates that MYNZ may have some problems paying its short term obligations.
With a Current ratio value of 0.52, MYNZ is not doing good in the industry: 92.09% of the companies in the same industry are doing better.
A Quick Ratio of 0.43 indicates that MYNZ may have some problems paying its short term obligations.
With a Quick ratio value of 0.43, MYNZ is not doing good in the industry: 92.28% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.43
MYNZ Yearly Current Assets VS Current LiabilitesMYNZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.47% over the past year.
Looking at the last year, MYNZ shows a decrease in Revenue. The Revenue has decreased by -0.17% in the last year.
The Revenue has been growing by 26.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.55%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%-44.95%

3.2 Future

MYNZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.04% yearly.
The Revenue is expected to grow by 133.71% on average over the next years. This is a very strong growth
EPS Next Y83.39%
EPS Next 2Y38.62%
EPS Next 3Y24.17%
EPS Next 5Y15.04%
Revenue Next Year-17.68%
Revenue Next 2Y-7.02%
Revenue Next 3Y32.9%
Revenue Next 5Y133.71%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MYNZ Yearly Revenue VS EstimatesMYNZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
MYNZ Yearly EPS VS EstimatesMYNZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MYNZ. In the last year negative earnings were reported.
Also next year MYNZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYNZ Price Earnings VS Forward Price EarningsMYNZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYNZ Per share dataMYNZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

MYNZ's earnings are expected to grow with 24.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y24.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MYNZ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MAINZ BIOMED NV

NASDAQ:MYNZ (12/12/2025, 8:00:01 PM)

After market: 1.07 +0.04 (+3.88%)

1.03

-0.02 (-1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-26 2025-09-26
Earnings (Next)03-30 2026-03-30/amc
Inst Owners5.62%
Inst Owner ChangeN/A
Ins Owners0.84%
Ins Owner ChangeN/A
Market Cap8.84M
Revenue(TTM)894.00K
Net Income(TTM)-21.65M
Analysts82.86
Price Target14.28 (1286.41%)
Short Float %4.81%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)26.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.89
P/FCF N/A
P/OCF N/A
P/B 3.5
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.36
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.8
OCFYN/A
SpS0.1
BVpS0.29
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -220.85%
ROE -858.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.31%
FCFM N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.98%
Cap/Sales 31.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.43
Altman-Z -16.31
F-Score5
WACC6.09%
ROIC/WACCN/A
Cap/Depr(3y)139.31%
Cap/Depr(5y)92.63%
Cap/Sales(3y)121.7%
Cap/Sales(5y)74.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.55%
EPS Next Y83.39%
EPS Next 2Y38.62%
EPS Next 3Y24.17%
EPS Next 5Y15.04%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%-44.95%
Revenue Next Year-17.68%
Revenue Next 2Y-7.02%
Revenue Next 3Y32.9%
Revenue Next 5Y133.71%
EBIT growth 1Y30.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.02%
OCF growth 3YN/A
OCF growth 5YN/A

MAINZ BIOMED NV / MYNZ FAQ

What is the fundamental rating for MYNZ stock?

ChartMill assigns a fundamental rating of 2 / 10 to MYNZ.


Can you provide the valuation status for MAINZ BIOMED NV?

ChartMill assigns a valuation rating of 1 / 10 to MAINZ BIOMED NV (MYNZ). This can be considered as Overvalued.


Can you provide the profitability details for MAINZ BIOMED NV?

MAINZ BIOMED NV (MYNZ) has a profitability rating of 1 / 10.


How financially healthy is MAINZ BIOMED NV?

The financial health rating of MAINZ BIOMED NV (MYNZ) is 1 / 10.